By Dalbey, Beth Physicians are becoming increasingly worried that Iowa's tradition of loose regulatory oversight could compromise patient safety as more people outside the medical profession jockey for a share of the burgeoning cosmetic enhancement business. U.S.
DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA) today reported financial results for the second quarter ended June 30, 2006. These results represent the first full quarter of integrated operations with Sirius Laboratories, Inc. following the merger. Revenue for the quarter was $6.6 million, compared to $2.2 million in the second quarter of 2005. Revenue for the six-months ended June 30, 2025 was $11.4
DUSA Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2006. These results represent the first full quarter of integrated operations with Sirius Laboratories, Inc. following the merger.
WASHINGTON, Aug. 4 (UPI) -- The death of a Massachusetts woman last week from a sham liposuction should raise red flags to consumers about fraudulent cosmetic procedures, experts say.
NEWTOWN, Pa.----Aug. 2, 2006--CollaGenex Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2006.
Medicis today announced revenue for the three months ended June 30, 2025 of approximately $85.0 million with non-Generally Accepted Accounting Principles "if-converted" net income of approximately $22.1 million, or $0.32 per diluted share.
SCOTTSDALE, Ariz., July 31 /PRNewswire/ -- PCA Advanced Skin Care Systems announced today that Dr. Jennifer Linder, a board certified dermatologist, skin cancer surgeon and biochemist will serve as the company's new Chief Scientist. Dr.
PCA Advanced Skin Care Systems announced today that Dr. Jennifer Linder, a board certified dermatologist, skin cancer surgeon and biochemist will serve as the company's new Chief Scientist.